Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis
暂无分享,去创建一个
S. H. Lee | S. Jung | Y. Ko | S. Kim | J. Mok | S. Kwon | T. An | Y. Jeong | Hyung-Woo Kim | J. Min | Wan Seo | E. Lee | Yeonhee Park | Sun-Hyung Kim | J. Y. Oh | Jin Woo Kim | J. S. Kim
[1] J. Myong,et al. Prevalence of latent tuberculosis infection among participants of the national LTBI screening program in South Korea – A problem of low coverage rate with current LTBI strategy , 2023, Frontiers in Public Health.
[2] S. H. Lee,et al. Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study , 2022, PloS one.
[3] Sohee Park,et al. Author Correction: Hidden loss to follow-up among tuberculosis patients managed by public–private mix institutions in South Korea , 2022, Scientific Reports.
[4] T. Shim,et al. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis , 2021, Antimicrobial agents and chemotherapy.
[5] D. Kim,et al. Developing a Diagnostic Bundle for Bronchiectasis in South Korea: A Modified Delphi Consensus Study , 2021, Tuberculosis and respiratory diseases.
[6] S. H. Lee,et al. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study , 2020, BMC Infectious Diseases.
[7] K. Floyd,et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data , 2020, PLoS medicine.
[8] Ross J. Harris,et al. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance , 2019, European Respiratory Journal.
[9] T. Shim,et al. Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance , 2018, Tuberculosis and respiratory diseases.
[10] Jong Sun Park,et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. , 2018, The Lancet. Respiratory medicine.
[11] H. Jenkins,et al. Isoniazid-resistant tuberculosis: a cause for concern? , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] A. Benedetti,et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. , 2017, The Lancet. Infectious diseases.
[13] A. Catanzaro,et al. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review , 2015, PloS one.
[14] H. Jenkins,et al. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009 , 2011, PloS one.
[15] J. Winner,et al. Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus , 2009, Infection and drug resistance.
[16] M. Pai,et al. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis , 2008, European Respiratory Journal.
[17] G. Bai,et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[18] M. Iseman,et al. Tuberculosis therapy: past, present and future , 2002, European Respiratory Journal.
[19] D. Hunter,et al. Qualitative Research: Consensus methods for medical and health services research , 1995 .
[20] J. Belaiche,et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid , 1995, Hepatology.
[21] C. Dolea,et al. World Health Organization , 1949, International Organization.